Breaking News Bar
updated: 10/11/2013 1:14 PM

Amarin fish oil pill gets mixed FDA assessment

Success - Article sent! close
Bloomberg News

A study of Amarin Corp.'s fish oil drug uncovered no new safety risks, though the benefit of expanding use to people with "very high" triglycerides needs to first be weighed against separate studies, U.S. regulators said.

Food and Drug Administration staff made the determination about the prescription-grade omega-3 fatty acid, called Vascepa, in a report posted today. A panel of FDA advisers is scheduled to meet Oct. 16 to discuss expanded approval for the drug to people with only "high" triglycerides, a fat in the blood, who also are using a cholesterol-lowering statin.

Article Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.